InsiderTrades.com logo

SILO Insider Trading

Insider Ownership Percentage: 2.22%
Insider Buying (Last 12 Months): $6,770.00
Insider Selling (Last 12 Months): $0.00

Silo Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at Silo Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Silo Pharma Share Price & Price History

Current Price: $0.45
Price Change: ▼ Price Decrease of -0.0041 (-0.90%)
As of 12/4/2025 05:00 PM ET

This chart shows the closing price history over time for SILO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Silo Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2025Eric WeisblumCEOBuy1,000$0.37$370.00210,932View SEC Filing Icon  
5/27/2025Eric WeisblumCEOBuy10,000$0.43$4,300.00197,932View SEC Filing Icon  
12/13/2024Eric WeisblumCEOBuy2,500$0.84$2,100.00187,932View SEC Filing Icon  
11/22/2024Eric WeisblumCEOBuy2,500$0.90$2,250.00185,432View SEC Filing Icon  
11/20/2024Eric WeisblumCEOBuy2,500$0.95$2,375.00182,932View SEC Filing Icon  
6/11/2024Eric WeisblumCEOBuy562$1.08$606.96175,994View SEC Filing Icon  
4/4/2024Eric WeisblumCEOBuy600$1.96$1,176.00175,032View SEC Filing Icon  
4/1/2024Eric WeisblumCEOBuy1,100$1.91$2,101.00174,432View SEC Filing Icon  
3/28/2024Eric WeisblumCEOBuy3,408$1.94$6,611.52173,332View SEC Filing Icon  
12/19/2023Eric WeisblumCEOBuy500$1.63$815.00169,724View SEC Filing Icon  
12/14/2023Eric WeisblumCEOBuy200$1.50$300.00168,324View SEC Filing Icon  
12/7/2023Eric WeisblumCEOBuy324$1.36$440.64168,124View SEC Filing Icon  
12/5/2023Eric WeisblumCEOBuy600$1.39$834.00167,724View SEC Filing Icon  
11/30/2023Eric WeisblumCEOBuy1,000$1.53$1,530.00167,124View SEC Filing Icon  
11/27/2023Eric WeisblumCEOBuy250$1.78$445.00165,124View SEC Filing Icon  
11/22/2023Eric WeisblumCEOBuy400$1.68$672.00164,874View SEC Filing Icon  
11/16/2023Eric WeisblumCEOBuy1,100$1.33$1,463.00158,324View SEC Filing Icon  
5/26/2023Daniel E RyweckCFOBuy1,000$2.13$2,130.005,000View SEC Filing Icon  
5/17/2023Eric WeisblumCEOBuy2,500$2.06$5,150.00157,224View SEC Filing Icon  
12/19/2022Eric WeisblumCEOBuy200$2.68$536.00154,724View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Silo Pharma (NASDAQ:SILO)

5.58% of Silo Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SILO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Silo Pharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/17/2025Anson Funds Management LP952,381$0.66M0.1%N/A7.150%Search for SEC Filing on Google Icon
11/14/2025Virtu Financial LLC107,786$74K0.0%N/A0.809%Search for SEC Filing on Google Icon
11/5/2025AdvisorShares Investments LLC364,878$0.25M0.0%+98.0%2.740%Search for SEC Filing on Google Icon
8/4/2025AdvisorShares Investments LLC184,236$0.12M0.0%+48.3%4.112%Search for SEC Filing on Google Icon
2/13/2025Renaissance Technologies LLC37,500$33K0.0%-83.5%0.837%Search for SEC Filing on Google Icon
11/20/2024Virtu Financial LLC25,615$28K0.0%-38.8%0.571%Search for SEC Filing on Google Icon
5/11/2023Financial Advocates Investment Management44,507$93K0.0%+196.6%1.408%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Silo Pharma logo
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Read More on Silo Pharma

Today's Range

Now: $0.45
Low: $0.45
High: $0.46

50 Day Range

MA: $0.54
Low: $0.36
High: $0.77

52 Week Range

Now: $0.45
Low: $0.36
High: $3.37

Volume

64,513 shs

Average Volume

139,477 shs

Market Capitalization

$6.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36

Who are the company insiders with the largest holdings of Silo Pharma?

Silo Pharma's top insider investors include:
  1. Eric Weisblum (CEO)
Learn More about top insider investors at Silo Pharma.

Who are the major institutional investors of Silo Pharma?

Silo Pharma's top institutional shareholders include:
  1. Anson Funds Management LP — 7.15%
  2. AdvisorShares Investments LLC — 2.74%
  3. Virtu Financial LLC — 0.81%
Learn More about top institutional investors of Silo Pharma stock.

Which institutional investors are buying Silo Pharma stock?

Within the previous quarter, SILO stock was purchased by institutional investors including:
  1. Anson Funds Management LP
  2. AdvisorShares Investments LLC
  3. Virtu Financial LLC